Royal Bank Of Canada Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective cut by investment analysts at Royal Bank Of Canada from $779.00 to $762.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of […]
2 May 08:46 · The Cerbat Gem